Clinical Trial: Upadacitinib for Refractory Behcet's Syndrome
Study Status: COMPLETED
Recruit Status: COMPLETED
Condition: Behcet Syndrome
Study Type: INTERVENTIONAL
Official Title: Upadacitinib for Refractory Behcet's Syndrome: a Prospective Pilot Open-label Study
Brief Summary:
Behçet's syndrome (BS) is a systemic autoimmune vasculitis that can affect multiple organs, including the skin, eyes, and vascular system.Refractory BS poses significant treatment challenges, necessitating novel therapeutic approaches.Upadacitinib, a selective JAK1 inhibitor within the JAK-STAT pathway, has shown promise in modulating immune responses.This study aims to evaluate the efficacy and safety of upadacitinib in patients with refractory BS.
Read more